Multiresistant Gram-negative infections: A global perspective

Current Opinion in Infectious Diseases

Volumn 23, Issue 6, 2010, Pages 546-553

  Ho, Jennifer ^a   Tambyah, Paul A ^a   Paterson, David L ^b  

^a NATIONAL UNIVERSITY HOSPITAL   (Singapore)

^b UNIVERSITY OF QUEENSLAND   (Australia)

Author keywords

antibiotic resistance; beta lactamase; Gram negative infection; nosocomial

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC AGENT; BETA LACTAMASE AMPC; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CEFTRIAXONE; CEPHALOSPORIN; CIPROFLOXACIN; CLAVULANIC ACID; COLISTIN; COTRIMOXAZOLE; DORIPENEM; ERTAPENEM; EXTENDED SPECTRUM BETA LACTAMASE; GENTAMICIN; IMIPENEM; LEVOFLOXACIN; MEROPENEM; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN; POLYMYXIN B; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; SULTAMICILLIN; TAZOBACTAM; TIGECYCLINE; TOBRAMYCIN;

ABDOMINAL INFECTION; ANTIBIOTIC RESISTANCE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BLOODSTREAM INFECTION; DRUG BINDING SITE; DRUG PENETRATION; DRUG SENSITIVITY; ENZYME SYNTHESIS; GENE MUTATION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HEALTH CARE FACILITY; HORIZONTAL GENE TRANSFER; HOSPITAL INFECTION; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PHENOTYPE; PREVALENCE; PSEUDOMONAS AERUGINOSA; REVIEW; SKIN INFECTION; SOFT TISSUE INFECTION; URINARY TRACT INFECTION; VANCOMYCIN RESISTANT ENTEROCOCCUS; VENTILATOR ASSOCIATED PNEUMONIA; VULNERABLE POPULATION;

ANTI-BACTERIAL AGENTS; COMMUNICABLE DISEASE CONTROL; COMMUNITY-ACQUIRED INFECTIONS; CROSS INFECTION; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-NEGATIVE BACTERIA; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; WORLD HEALTH;

EID: 78349311509     PISSN: 09517375     EISSN: 14736527     Source Type: Journal    
DOI: 10.1097/QCO.0b013e32833f0d3e     Document Type: Review

References (111)

1. Gaynes R, Edwards JR. Overview of nosocomial infections caused by Gram-negative bacilli. Clin Infect Dis 2005; 41:848-854.
2. Albrecht SJ, Fishman NO, Kitchen J, et al. Reemergence of Gramnegative healthcare-associated bloodstream infections. Arch Intern Med 2006; 166:1289-1294.
3. Boucher HW,TalbotGH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update for the Infectious Diseases Society of America. Clin Infect Dis 2009; 48:1-12.
4. Weldhagen G, Poirel L, Nordmann P. Ambler class A extended-spectrum β-lactamase in Pseudomonas aeruginosa: novel development and clinical impact. Antimicrob Agents Chemother 2003; 47:2385-2392.
5. Cheng KC, Chuang YC, Wu LT, et al. Clinical experiences of the infections caused by extended-spectrum β-lactamase-producing Serratia marcescens at a medical center in Taiwan. Jpn J Infect Dis 2006; 59:147-152.
6. Manzur A, Tubau F, Pujol M, et al. Nosocomial outbreak due to extended-spectrum β-lactamase-producing Enterobacter cloacae in a cardiothoracic intensive care unit. J Clin Microbiol 2007; 45:2365-2369.
7. Choi SH, Lee JE, Park SJ, et al. Prevalence, microbiology and clinical characteristics of extended-spectrum β-lactamase-producing Enterobacter spp., Serratia marcescens, Citrobacter freundii and Morganella morganii in Korea. Eur J Clin Microbiol Infect Dis 2007; 26:557-561.
8. Medeiros A. β-lactamases. Br Med Bull 1984; 40:18-27.
9. st century; characterization, epidemiology and detection of this important resistance threat. Clin Microbiol Rev 2001; 14:933-951.
10. Paterson DL, Bonomo RA. Extended-spectrum β-lactamases: a clinical update. Clin Microbiol Rev 2005; 18:657-686.
11. Rossolini GM, Docquier JD. New beta-lactamases: a paradigm for the rapid response of bacterial evolution in the clinical setting. Future Microbiol 2006; 1:295-308.
12. Peleg AY, Hooper DC. Hospital-acquired infections due to Gramnegative bacteria. N Engl J Med 2010; 362:1804-1813.
13. Jacoby GA. AmpC β-lactamases. Clin Microbiol Rev 2009; 22:161-182.
14. Poirel L, Heritier C, Spicq C, et al. In vivo acquisition of high-level resistance to imipenem in Escherichia coli. J Clin Micrbiol 2004; 42:3831-3833.
15. Livermore DM, Woodford N. The beta-lactamase threat in Enterobacteria-ceae, Pseudomonas and Acinetobacter. Trends Microbiol 2006; 14:413-420.
16. Elliot E, Brink AJ, van Greune J, et al. In vivo development of ertapenem resistance in a patient with pneumonia caused by Klebsiella pneumonia with extended-spectrum beta-lactamase. Clin Infect Dis 2006; 42:95-98.
17. Lolans K, Queenan AM, Bush K, et al. First nosocomial outbreak of Pseudomonas aeruginosa producing an integron-borne met allo-β-lactamase (VIM-2) in the United States. Antimicrob Agents Chemother 2005; 49:3538-3540.
18. 8 in a university medical center in Taiwan. J Clin Microbiol 2001; 39:4433-4439.
19. Laupland KB, Parkins MD, Church DL, et al. Population-bases epidemiolo-gical study of infection caused by carbapenem-resistant Pseudomonas aeruginosa in Calgary Health Region: importance of met allo-β-lactamases (MBL)-producing strains. J Infect Dis 2005; 192:1606-1612.
20. Tsakris A, Ikonomidis A, Poulou A, et al. Clusters of imipenem-resistant Acinetobacter baumannii clones producing different carbapenemases in an intensive care unit. Clin Micrbiol Infect 2008; 14:588-594.
21. VIM-7 carbapene-mase-producing Pseudomonas aeruginosa isolates detected in a tertiary care medical center in the United States: report from the MYSTIC program. J Clin Microbiol 2007; 45:614-615.
22. NordmassP, Poirel L.Emerging carbapenemasesinGramnegative aerobes. Clin Micrbio Infect 2002; 8:321-331.
23. Poirel L, Naas T, Nicholas D, et al. Characterization of VIM-2, a carbapenen-hydrolyzing met allo-beta-lactamase and its plasmid and integron-borne gene from a Pseudomonas aeruginosa clinical isolate in France. Antimicrob Agents Chemother 2000; 44:891-897.
24. Heritier C, Poirel L, Lambert T, Nordmann P. Contribution of acquired carbapenem-hydrolyzing oxacillinases to carbapenem resistance in Acine-tobacter baumannii. Antimicrob Agents Chemother 2005; 49:3198-3202.
25. Walsh TR. Clinically significant carbapenemases: an update. Curr Opin Infect Dis 2008; 21:367-371.
26. VIM-2 harboring integrons isolated in India, Russia and the United States arise from an ancestral class 1 integron predating the formation of the 3' conservative sequence. Antimicrob Agents Chemother 2007; 51:2636-2638.
27. Deplano A, Rodriguez-Villalobos H, Glupczynski Y, et al. Emergence and dissemination of multidrug resistant clones of Pseudomonas aeruginosa producing VIM-2 met allo-beta-lactamase in Belgium. Euro Surveill 2007; 12:E070118.2.
28. Khosravi AD, Mihani F. Detection of met allo-beta-lactamase-producing Pseu-domonas aeruginosa strains isolated from burn patients in Ahwaz, Iran. Diagn Microbiol Infect Dis 2008; 60:125-128.
29. Cagnacci S, Guaico L, Roveta S, et al. Bloodstream infections caused by multidrug resistant Klebsiella pneumonia producing the carbapenem-hydro-lysing VIM-1 met allo-beta-lactamase: first Italian outbreak. J Antimicrob Chemother 2008; 61:296-300.
30. Souli M, Kontopidou FV, Papadomichelakis E, et al. Clinical experience of serious infections caused by Enterobacteriaceae producing VIM-1 met allo-beta-lactamase in a Greek University Hospital. Clin Infect Dis 2008; 46: 847-854.
31. Yidirim I, Ceyhan M, Gur D, et al. First detection of VIM-1 type met allo-beta-lactamase in multidrug-resistant Klebsiella pneumoniae clinical isolate from Turkey also producing the CTX-M-15 extended spectrum beta-lactamase. J Chemother 2007; 19:467-468.
32. Galani I, Souli M, Koratzanis E, et al. Emerging bacterial pathogens: Escher-ichia coli, Enterobacter aerogenes and Proteus mirabilis clinical isolates harbouring the same transferable plasmid coding for met allo-beta-lactamase VIM-1 in Greece. J Antimicrob Chemother 2007; 59:578-579.
33. Tsakris A, Ikonomidis A, Poulou A, et al. Transmission in the community of clonal Proteus mirabilis carrying VIM-1 met allo-beta-lactamase. J Antimicrob Chemother 2007; 60:136-139.
34. Yong D, Toleman MA, Giske CG, et al. Characterisation of a new met allo-beta-lactamase gene, bla(NDM-1), and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumonia sequence type 14 from India. Antimicrob Agents Chemother 2009; 52:5046-5054.
35. Drlica K, Malik M. Fluoroquinolones: action and resistance. Curr Top Med Chem 2003; 3:249-282
36. EARSSAnnualreport2007.On-goingsurveillanceofS.pneumonia,S.aureus, E. faecalis, E. faecium, E. coli, K. pneumoniae and P. aeruginosae. 2007.
37. Lavilla S, Gonzalez-Lopez JJ, Sabate M, et al. Prevalence of qnr genes among extended-spectrum b-lactamase-producing enterobacterial isolates in Barcelona, Spain. J Antimicrob Chemother 2008; 61:291-295.
38. Nikaido H. Molecular basis of bacterial outer membrane permeability revisited. Microbiol Mol Biol Rev 2003; 67:593-656.
39. Stover CK, Pham XQ, Erwin AL, et al. Complete genome sequence of Pseudomonas aeruginosa PA01, an opportunistic pathogen. Nature 2000; 406:959-964.
40. Hernandez-Alles S, Alberti S, Alvarez D, et al. Porin expression in clinical isolates of Klebsiella pneumonia. Microbiology 1999; 145:673-679.
41. Mussi MA, Limansky AS, Viale AM. Acquisition of resistance to carbapenems in multidrug resistant clinical strains of Acinetobacter baumannii: natural insertional inactivation of a gene encoding a member of a novel family of beta-barrel outer membrane proteins. Antimicrob Agents Chemother 2005; 49:1432-1440.
42. Magnet S, Courvalin P, Lambert T. Resistance-nodulation-cell-division- type efflux pump involved in aminoglycoside resistance in Acinetobacter baumannii strain BM4454. Antimicrob Agents Chemother 2001; 45:3375-3380.
43. Chau SL, Chu YW, Houang ET. Novel resistance-nodulation-cell division efflux system AdeDE in Acinetobacter genomic DNA group 3. Antimicrob Agents Chemother 2004; 48:4054-4055.
44. Projan SJ, Bradford PA. Late stage antibacterial drugs in the clinical pipeline. Curr Opin Microbiol 2007; 10:441-446.
45. Yigit H, Queenan AM, Anderson GJ, et al. Novel carbapenem-hydrolyzing β-lactamase, KPC-1, from a carbapenem-resistant strain of Klebsiella pneumonia. Antimicrob Agents Chemother 2001; 45:1151-1161.
46. Bratu S, Landman D, Haag R, et al. Rapid spread of carbapenem-resistant Klebsiella pneumonia in New York City. A new threat to our antibiotic armamentarium. Arch Intern Med 2005; 165:1430-1435.
47. Rasheed JK, Biddle JW, Anderson KF, et al. Detection of the Klebsiella pneumonia carbapenemase type 2 carbapenem-hydrolyzing enzyme in clinical isolates of Citrobacter freundii and K oxytoca carrying a common plasmid. J Clin Microbiol 2008; 46:2066-2069.
48. Deshapande LM, Rhomberg PR, Sader HS, et al. Emergence of serine carbapenemases (KPC and SME) among clinical strains of Enterobacter-iaceae isolated in the United States Medical Centers: report from the MYSTIC Program (1995-2005). Diagn Microbiol Infect Dis 2006; 56:367-372.
49. Villegas MV, Lolans K, Correa A, et al. First identification of Pseudomonas aeruginosa isolates producing a KPC-type carbapenem-hydrolyzing β-lac-tamase. Antimicrob Agents Chemother 2007; 51:1553-1555.
50. Naas T, Nordmann P, Vedel G, et al. Plasmid-mediated carbapenem- hydrolyzing β-lactamase KPC in a Klebsiella pneumoniae isolate from France. Antimicrob Agents Chemother 2005; 49:4423-4424.
51. Wei ZQ, Du XX, Yu YS, et al. Plasmid mediated KPC-2 in a Klebsiella pneumonia isolate from China. Antimicrob Agents Chemother 2007; 51:763-765.
52. Cuzon G, Naas T, Demachy MC, et al. Plasmid mediated carbapenem hydrolyzing β-lactamase KPC-2 in Klebsiella pneumoniae isolated from Greece. Antimicrob Agents Chemother 2008; 52:796-797.
53. Monteiro J, Santos AF, Asensi MD, et al. First report of KPC-2 producing Klebsiella pneumonia strains in Brazil. Antimicrob Agents Chemother 2009; 53:333-334.
54. Baraniak A, Izdebski R, Herda M, et al. The emergence of Klebsiella pneumonia ST258 with KPC-2 in Poland. Antimicrob Agents Chemother 2009; 53:4565-4567.
55. Samuelsen O, Naseer U, Tofteland S, et al. Emergence of clonally related Klebsiella pneumonia isolates of sequence type 258 producing plasmid-mediated KPC carbapenemase in Norway and Sweden. J Antimicrob Chemother 2009; 63:654-658.
56. Woodford N, Zhang J, Warner M, et al. Arrival of Klebsiella pneumonia producing KPC carbapenemase in the United Kingdom. J Antimicrob Chemother 2008; 62:1261-1264.
57. Akpaka PE, Swanston WH, Ihemere HN, et al. Emergence of KPC-producing Pseudomonas aeruginosa in Trinidad and Tobago. J Clin Microbiol 2009; 47:2670-2671.
58. Pournaras S, Protonotariou E, Voulgari E, et al. Clonal spread of KPC-2 carbapenemase-producing Klebsiella pneumoniae strains in Greece. J Antimicrob Chemother 2009; 64:348-352.
59. Leavitt A, Navon-Venezia S, Chmelnitsky I, et al. Emergence of KPC-2 and KPC-3 in carbapenem-resistant Klebsiella pneumonia strains in an Israeli hospital. Antimicrob Agents Chemother 2007; 51:3026-3029.
60. Navon-Venezia S, Chmelnitsky I, Leavitt A, et al. Plasmid-mediated imipenem-hydrolyzing enzyme KPC-2 among multiple carbapenem-resistant Escher-ichia coli clones in Israel. Antimicrob Agents Chemother 2006; 50:3098-3101.
61. Dortet L, Radu I, Gautier V. Intercontinental travels of patients and dissemination of plasmid-mediated carbapenemase KPC-3 associated with OXA-9 and TEM-1. J Antimicrob Agents 2007; 61:455-457.
62. Rhomberg PR, Jones RN. Summary trends for the meropenem yearly susceptibility test information collection program: a 10-year experience in the United States (1999-2008). Diagn Microbiol Infect Dis 2009; 65:414-426.
63. Turner PJ. MYSTIC Europe 2007: activity of meropenem and other broad-spectrum agents against nosocomial isolates. Diagn Microbiol Infect Dis 2009; 63:217-222.
64. Hanberger H, Diekema D, Fluit A, et al. Surveillance of antibiotic resistance in European ICUs. J Hosp Infect 2001; 48:161-176.
65. Reynolds R. Antimicrobial resistance in the UK and Ireland. J Antimicrob Chemother 2009; 64S1:i19-i23.
66. Goossens H, Grabein B. Prevalence and antimicrobial susceptibility data for extended-spectrum beta-lactamase and AmpC producing Enterobacteria-ceae from the MYSTIC program in Europe and the United States (1997-2004). Diagn Micrbiol Infect Dis 2005; 53:257-264.
67. Moet GJ, Jones RN, Biedenbach DJ, et al. Contemporary causes of skin and soft tissue infections in North America, Latin America dn Europe: report from the SENTRY antimicrobial surveillance program (1998-2004). Diagn Microbiol Infect Dis 2007; 57:7-13.
68. Pitout JD, Nordmann P, Laupland KB, Poirel L. Emergence of Enterobacter-iaceae producing extended-spectrum beta-lactamases (ESBLs) in the community. J Antimicrob Chemother 2005; 56:52-59.
69. Bonnet R. Growing group of extended spectrum beta-lactamases: the CTX-M enzymes. Antimicrob Agents Chemother 2004; 48:1-14.
70. Canton R, Coque TM. The CTX-M beta-lactamase pandemic. Curr Opin Microbiol 2006; 9:466-475.
71. Karsik E, Ellington MJ, Pike R, et al. Molecular characterization of plasmids encoding CTX-M 15 beta-lactamases from Escherichia coli strains in the United Kingdom. J Antimicrob Chemother 2006; 58:665-668.
72. Mugnaioli C, Luzzaro F, De Luca F, et al. CTX-M-type extended spectrum beta-lactamases in Italy: molecular epidemiology of an emerging countrywide problem. Antimicrob Agents Chemother 2006; 50:2700-2706.
73. Livermore DM, Canton R, Gniadkowski M, et al. CTX-M: changing the face of ESBLs in Europe. J Antimicrob Chemother 2007; 59:165-174.
74. Bouchillon SK, Irdell JR, Barkham T, et al. Comparative in vitro activity of tigecycline and other antimicrobials against Gramnegative and Gram-positive organisms collected from the Asia-Pacific rim as part of the tigecycline evaluation and surveillance trial (TEST). Int J Antimicrob Agents 2009; 33:130-136.
75. Reinert RR, Low DE, Rossi F, et al. Antimicrobial susceptibility among organisms from the Asia/Pacific rim, Europe and Latin and North America collected as part of TEST and the in vitro activity of tigecycline. J Antimicrob Chemother 2007; 60:1018-1029.
76. Coelho JM, Turton JF, Kaufmann ME, et al. Occurrence of carbapenem-resistant Acinetobacterbaumanniiclones at multiple hospitals in London and Southeast England. J Clin Microbiol 2006; 44:3623-3627.
77. Van Dessel H, Dijkshoorn L, van der Reijden T, et al. Identification of a new geographically widespread multiresistant Acinetobacter baumannii clone from European hospitals. Res Microbiol 2004; 155:105-112.
78. Hidron AI, Edwards JR, Patel J. NHSN annual update: antimicrobial- resistant pathogens associated with healthcare-associated infections: annual summary of data reported to the National Healthcare Safety Network at the Center for Disease Control and Prevention, 2006-2007. Infect Control Hosp Epidemiol 2008; 29:996-1011.
79. Go ES, Urban C, Burns J, et al. Clinical and molecular epidemiology of Acinetobacter infections sensitive only to polymixinB and sulbactam. Lancet 1994; 344:1329-1332.
80. Shigemi A, Matsumoto K, Yaji K, et al. Correlation between meropenem and doripenem use density and the incidence of carbapenem-resistant Pseudomonas aeruginosa. Int J Antimicrob Agents 2009; 34:589-591.
81. Al-Aloul M, Miller H, Alapati S, et al. Renal impairment in cystic fibrosis patients due to repeated intravenous aminoglycoside use. Pediatr Pulmonol 2005; 39:15-20.
82. Pereira GH, Muller PR, Levin AS. Salvage treatment of pneumonia and initial treatment of tracheobronchitis caused by multiresistant Gramnegative bacilli with inhaled polymyxin B. Diagn Microb Infect Dis 2007; 58:235-240.
83. Livermore DM, Hill RLR, Thomson H, et al. Antimicrobial treatment and clinical outcome for infections with carbapenem and multiply resistant Acinetobacter baumannii around London. J Antimicrob Agents 2010; 35:19-24.
84. Antoniadou A, Kontopidou F, Poulakou G, et al. Colistin-resistant isolates of Klebsiella pneumonae emerging in intensive-care unit patients: first report of a multiclonal cluster. J Antimicrob Chemother 2007; 59:786-790.
85. Johansen HK, Moskowitz SM, Ciofu O, et al. Spread of colistin resistant nonmucoid Pseudomonas aeruginosa among chronically infected Danish cystic fibrosis patients. J Cyst Fibros 2008; 7:391-397.
86. Beno P, Krcmery V, Demitrovicova A. Bacteremia in cancer patients caused by colistin-resistant Gramnegative bacilli after previous exposure to cipro-floxacin and/or colistin. Clin Microbial Infect 2006; 12:497-498.
87. Ko KS, Suh JY, Kwon KT, et al. High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea. J Antimicrob Chemother 2007; 60:1163-1167.
88. Yau W, Owen RJ, Poudyal A, et al. Colistin hetero-resistance in multidrug-resistant Actinetobacter baumannii clinical isolates from the Western Pacific region in the SENTRY antimicrobial surveillance program. J Infect 2009; 58:138-144.
89. Li J, Rayner CR, Nation RL, et al. Hetero-resistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 2006; 50:2946-2950.
90. Hawley JS, Murray CK, Jorgensen JH. Colistin heteroresistance in Acineto-bacter and its association with previous colistin therapy. Antimicrob Agents Chemother 2008; 52:351-352.
91. Koarageorgopoulos DE, Kelesidis T, Kelesidis I, Falagas ME. Tigecycline for the treatment of multidrug-resistant (including carbapenem-resistant) Aci-netobacter infections: a review of the scientific evidence. J Antimicrob Chemother 2008; 62:45-55.
92. Peleg AY, Potoski BA, Rea R, et al. Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. J Antimicrob Che-mother 2007; 59:128-131.
93. Hornsey M, Ellington MJ, Doumith M, et al. AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii. J Anti-microb Chemother 2010; 65:1589-1593.
94. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumonia carbapenemases (KPCs): an emerging cause of multiresistant infection. J Antimicrob Chemother 2010; 1119-1125.
95. Souli M, Rekatsina PD, Chryssouli Z, et al. Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in met allo-beta-lactamase-producing Klebsiella penumoniae isolates. Antimi-crob Agents Chemother 2009; 53:2133-2135.
96. Lee J, Patel G, Huprikar S, et al. Decreased susceptibility to polymixin B during treatment for carbapenem-resistant Klebsiella pneumoniae infection. J Clin Microbiol 47:1611-1612.
97. Tripodi MF, Durante-Mangoni E, Fortunato R, et al. Comparative activities of colistin, rifampicin, imipenem and sulbactam/ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolated producing OXA-58 carbapenemases. Int J Antimicrob Agents 2007; 30:537-540.
98. Weiner J, Quinn JP, Bradford PA, et al. Multiple antibiotic resistant Klebsiella and Escherichia coli in nursing homes. J Am Med Assoc 1999; 281:517-523.
99. Asensio A, Oliver A, Gonzalez-Diego P, et al. Outbreak of a multiresistant Klebsiella pneumoniae strain in an intensive care unit: antibiotic use as a risk factor for colonization and infection. Clin Infect Dis 2000; 30:55-60.
100. Hsu LY, Tan TY, Tam VH, et al. Surveillance and correlation of antibiotic prescription and resistance of Gramnegative bacteria in Singaporean hospitals. Antimicrob Agents Chemother 2010; 54:1173-1178.
101. Rahal JJ, Urban C, Horn D, et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. J Am Med Assoc 1998; 280:1233-1237.
102. SHV-5 in a French university hospital. J Antimicrob Chemother 2006; 57:142-145.
103. Boyce JM, Pitet D. Healthcare infection control practices advisory committee, HICPAC/SHEA/APIC/IDSA Hand hygiene task force. Guidelines for hand hygiene in health-care settings. Recommendations of the healthcare infection control practices advisory committee and the HIPAC/SHEA/APIC/IDSA hand hygiene task force. Am J Infect Control 2002; 30:S1-46.
104. Denton M, Wilcox MH, Parnell P, et al. Role of environmental cleaning in controlling an outbreak of Acinetobacter baumannii on a neurosurgical intensive care unit. J Hosp Infect 2004; 56:106-110.
105. Borer A, Gilad J, Megreleshvili R, et al. Prevalence and control of Acineto-bacter baumannii skin colonization among medical intensive care patients [abstract K-1100]. In Program and abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC: American Society for Microbiology; 2003.
106. Lemmen SW, Hafner H, Zolldann D, et al. Distribution of multiresistant Gramnegative versus Gram-positive bacteria in the hospital inanimate environment. J Hosp Infect 2004; 56:191-197.
107. Robicsek A, Beaumont JL, Paule SM, et al. Universal surveillance for methicillin-resistant Staphylococcus aureus in 3 affiliated hospitals. Ann Intern Med 2008; 148:409-418.
108. Pronovost P, Needham D, Berenholtz S, et al. An intervention to decrease catheter-related bloodstream infections in the ICU. N Engl J Med 2006; 355:2725-2732.
109. Rello J, Afessa B, Anzueto A, et al. Activity of a silver-coated endotracheal tube in preclinical models of ventilator-associated pneumonia and a study after extubation. Crit Care Med 2010; 38:1135-1140.
110. Allegranzi B, Pittet D. Role of hand hygiene in healthcare-associated infection prevention. J Hosp Infect 2009; 73:305-315.
111. Rice SA, McDonald D, Kumar N, Kjelleberg S. The use of quorum-sensing blockers as therapeutic agents for the control of biofilm-associated infections. Curr Opin Investig Drugs 2005; 6:178-184.